Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2011

View Archived Issues

GSK and Theravance provide update on new treatments for COPD

Cepheid and FIND collaborate on Xpert HIV viral load test

PharmaMar begins phase I trial of antitumor agent PM-060184

Phase II data presented on tasocitinib in plaque psoriasis

Expression levels of miR-21 and RHOB gene have prognostic value in urinary bladder cancer

Anti-inflammatory agents enhance effects of tazarotene on comedonal acne

Heterosubtypic influenza A vaccine is safe and immunogenic in healthy adults

EV-075 has potent activity against influenza and Ebola/Marburg viruses in vivo

Merck Serono presents new prostanoid DP2 receptor ligands

FDA clears Medicago's phase I trial of H1N1 influenza VLP vaccine candidate

AstraZeneca to withdraw NDA for anticancer drug Iressa

Tacere Therapeutics reacquires Asian rights to RNAi-based agents targeting HCV

Takeda begins enrollment in phase III alogliptin study in China

European phase IIb study of Posidur meets primary endpoints

Nerviano Medical Sciences divulges new PARP-1 inhibitors

New PI3K inhibitors developed at Incyte

Daiichi Sankyo patents novel tachykinin receptor antagonists

QLT stops phase II trial of olopatadine punctal plug delivery system

Japanese scientists claim new inhibitors of kinesin-like protein KIF11

INTRUST trials of Novartis' Onbrez Breezhaler plus tiotropium meet primary endpoints

Kyowa Hakko Kirin offers overview of 2010

Phase IIb trial of AM-101 in acute inner ear tinnitus completes enrollment

Idenix Pharma reports on three clinical programs

FDA grants orphan status to Neuralstem for spinal cord stem cells in ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...